Alsius wins three-year GPO contract from Novation
Bill Worthen, president and CEO of Alsius, said: “This is the sixth contract that we have been awarded by a major hospital group purchasing organization (GPO) in the
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.